A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF

被引:15
作者
Hashemi, J
Lindström, MS
Asker, C
Platz, A
Hansson, J
Wiman, KG
机构
[1] Karolinska Hosp, Canc Ctr Karolinska, Dept Oncol Pathol, S-17176 Stockholm, Sweden
[2] Karolinska Hosp, Canc Ctr Karolinska, Dept Oncol Pathol, Res Lab Radiumhemmet, S-17176 Stockholm, Sweden
关键词
CDKN2A; p14ARF; p16; melanoma; p53; MDM2;
D O I
10.1016/S0304-3835(02)00027-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The CDKN2A locus on human chromosome 9p21 encodes two proteins, p16 and p14ARF, that mainly regulate cell cycle progression and cell survival via the pRb and p53 pathways, respectively. Germline mutations in CDKN2A have been linked to development of cutaneous melanoma in some families with hereditary melanoma. Due to overlapping open reading frames in exon 2, some mutations in this exon affect both p16 and p14ARF. We previously reported a 24 bp deletion in CDKN2A exon 2 in a patient with multiple primary melanomas and melanoma heredity. To further clarify the possible role of the 24 bp deletion for melanoma development, especially with respect to p14ARF, we have studied the cellular distribution and function of the resulting p14ARF del (77-84) and p16 del (62-69) mutant proteins. We found that p14ARF del (77-84) had decreased nucleolar localization, and was less efficient than wt p14ARF in stabilizing p53, inducing G1 cell cycle arrest, and inhibiting colony formation. The p16 del (62-69) mutant localized predominantly to the cytoplasm, did not induce G1 cell cycle arrest, and failed to suppress colony formation. We conclude that p14ARF del (77-84) has retained the ability to stabilize MDM2 and p53, but that it is less potent than wt p14ARF. This partial functional defect may complement the clearly defective p16 del (6269) mutant and thus contribute to melanoma development in patients carrying the 24 bp deletion in CDKN2A. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:211 / 221
页数:11
相关论文
共 34 条
  • [21] The p16INK4a/CDKN2A tumor suppressor and its relatives
    Ruas, M
    Peters, G
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1998, 1378 (02): : F115 - F177
  • [22] A NEW REGULATORY MOTIF IN CELL-CYCLE CONTROL CAUSING SPECIFIC-INHIBITION OF CYCLIN-D/CDK4
    SERRANO, M
    HANNON, GJ
    BEACH, D
    [J]. NATURE, 1993, 366 (6456) : 704 - 707
  • [23] The ARF/p53 pathway
    Sherr, CJ
    Weber, JD
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 2000, 10 (01) : 94 - 99
  • [24] Cancer cell cycles
    Sherr, CJ
    [J]. SCIENCE, 1996, 274 (5293) : 1672 - 1677
  • [25] STONE S, 1995, CANCER RES, V55, P2988
  • [26] The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2
    Stott, FJ
    Bates, S
    James, MC
    McConnell, BB
    Starborg, M
    Brookes, S
    Palmero, I
    Ryan, K
    Hara, E
    Vousden, KH
    Peters, G
    [J]. EMBO JOURNAL, 1998, 17 (17) : 5001 - 5014
  • [27] P19ARF stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2
    Tao, WK
    Levine, AJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) : 6937 - 6941
  • [28] Walker GJ, 1999, INT J CANCER, V82, P305, DOI 10.1002/(SICI)1097-0215(19990719)82:2<305::AID-IJC24>3.0.CO
  • [29] 2-Z
  • [30] Cooperative signals governing ARF-Mdm2 interaction and nucleolar localization of the complex
    Weber, JD
    Kuo, ML
    Bothner, B
    DiGiammarino, EL
    Kriwacki, RW
    Roussel, MF
    Sherr, CJ
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (07) : 2517 - 2528